Consensus statement for the treatment of infantile haemangiomas with propranolol

Area of Science:

• Paediatric Dermatology
• Vascular Anomalies

Background:

• Infantile haemangiomas often involute spontaneously but can necessitate early treatment.
• Certain haemangiomas pose risks including ulceration, functional impairment, and deformity.

Purpose of the Study:

• To provide a consensus statement for the treatment of infantile haemangiomas with oral propranolol.
• To guide early intervention strategies for high-risk infantile haemangiomas.

Main Methods:

• Development of a consensus statement by the Australasian Vascular Anomalies Network and Australasian Paediatric Dermatology Network.
• Review of evidence for oral propranolol treatment in infantile haemangiomas.

Main Results:

• Oral propranolol is recommended for infantile haemangiomas that are life-threatening, ulcerated, or cause significant impairment.
• Oral propranolol is considered safe and effective for treating infantile haemangiomas.
• Treatment with oral propranolol can be initiated in an outpatient setting for most healthy infants.

Conclusions:

• Early intervention with oral propranolol is crucial for specific infantile haemangiomas.
• Oral propranolol offers a safe and effective treatment option.
• Outpatient initiation of oral propranolol is feasible for eligible infants.